Vargas, AJ & Harris, CC Biomarker Development in the Age of Precision Medicine: Lung Cancer as a Case Study. Nat. Reverend Cancer 16(8), 525-537 (2016).
US Food and Drug Administration List of licensed or approved companion diagnostic devices (in vitro and imaging tools). https://www.fda.gov/media/119249/download (March 24, 2021),
Scheerens, H. et al. Current state of companion and complementary diagnostics: strategic considerations for development and launch. Clin. Transl. Science. ten(2), 84–92 (2017).
Vogel, CL et al. Efficacy and safety of trastuzumab monotherapy in the first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719–726 (2002).
Bang, YJ et al. Trastuzumab in Combination with Chemotherapy Versus Chemotherapy Alone for the Treatment of HER2-Positive Advanced Gastric or Gastroesophageal (ToGA) Junction Cancer: A Phase 3, Open-Label, Randomized Controlled Trial. Lancet 376(9742), 687–697 (2010).
A. et al. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Ann. Oncol. 28(1), 110-115 (2017).
Modi, S. et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with advanced, low-HER2 expressing breast cancer: results from a phase Ib study. J. Clin. Oncol. 38(17), 1887–1896 (2020).
Nardo, A. et al. The selective oral estrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonizing ER and bypassing endocrine resistance. Br. J. Cancer 120(3), 331–339 (2019).
Janes, M. et al. Targeting KRAS mutant cancers with a specific covalent G12C inhibitor. Cell 172(3), 578-589.e17 (2018).
Nuciforo, P. et al. Elevated HER2 protein levels are correlated with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol. Oncol. ten(1), 138-147 (2016).
Gallien, S., Bourmaud, A., Kim, SY & Domon, B. Technical considerations for large-scale parallel reaction monitoring analysis. J. Proteomics 100147–159 (2014).
Gallien, S., Kim, SY, and Domon, B. Large-scale targeted proteomics using internal standard triggered parallel reaction monitoring (IS-PRM). Mol. Cellular proteomics 14(6), 1630-1644 (2015).
Gallien, S. et al. Targeted proteomic quantification on a quadrupole-Orbitrap mass spectrometer. Mol. Cellular proteomics 11(12), 1709–1723 (2012).
Cifani, P. & Kentsis, A. High-sensitivity quantitative proteomics using automated multidimensional nano-flow chromatography and monitoring of accumulated ions on a quadrupole-orbitrap-linear ion trap mass spectrometer. Mol. Cellular proteomics 16(11), 2006-2016 (2017).
Kim, YJ, Gallien, S., van Oostrum, J. & Domon, B. Targeted proteomics strategy applied to biomarker assessment. Clin proteomics. Appl. seven(11-12), 739-747 (2013).
Peterson, AC, Russell, JD, Bailey, DJ, Westphall, MS & Coon, JJ Side-reaction monitoring for high-resolution, high-mass precision targeted quantitative proteomics. Mol. Cellular proteomics 11(11), 1475-1488 (2012).
Morales-Betanzos, California et al. Quantitative analysis by mass spectrometry of the expression of the PD-L1 protein, NOT-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol. Cellular proteomics 16(10), 1705-1717 (2017).
Do, Mr. et al. Clinical application of multiple reaction-mass spectrometry monitoring to human epidermal growth factor receptor 2 measurements as a potential diagnostic tool for the treatment of breast cancer. Clin. Chem. 66(10), 1339–1348 (2020).
Klaassen, T., Szwandt, S., Kapron, JT & Roemer, A. Validated quantification method for a peptide in rat serum using liquid chromatography/high-field asymmetric waveform ion mobility spectrometry. Rapid Common. Mass spectrum. 23(15), 2301-2306 (2009).
Xia, Y.-Q., Wu, ST & Jemal, M. LC-FAIMS-MS/MS for peptide quantification in plasma and assessment of overall FAIMS selectivity from plasma components. Anal. Chem. 80(18), 7137–7143 (2008).
Norman, RL, Singh, R., Langridge, JI, Ng, LL & Jones, DJL The measurement of KRAS G12 mutants using multiplexed selected reaction monitoring and ion mobility mass spectrometry. Rapid Common. Mass spectrum. 34(S4), e8657 (2020).
Doneanu, C. et al. An HS-MRM assay for the quantification of host cell proteins in protein biopharmaceuticals by liquid chromatography, ion mobility, QTOF mass spectrometry. J.Vis. Exp. 134e55325 (2018).
Cooper, HJ How beneficial is FAIMS in protein analysis?. Jam. Soc. Mass spectrum. 27(4), 566–577 (2016).
Renuse, S. et al. A targeted mass spectrometry-based test for the detection of SARS-CoV-2 antigen from clinical specimens. EBioMedicine 69103465 (2021).
MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26(7), 966–968 (2010).
Trachsell, C. et al. rawDiag: an R package supporting rational optimization of the LC-MS method for bottom-up proteomics. J. Proteome Res. 17(8), 2908-2914 (2018).
Sellman, C. et al. Balancing the selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR) × c-MET antibodies and antibody-drug conjugates. J. Biol. Chem. 291(48), 25106–25119 (2016).
Perry, RH, Cooks, RG & Noll, RJ Orbitrap Mass Spectrometry: Instrumentation, Ion Motion and Applications. Mass spectrum. Round. 27(6), 661–699 (2008).
Picotti, P. & Aebersold, R. Proteomics based on monitoring selected reactions: workflow, potential, pitfalls and future directions. Nat. Methods 9555–566 (2012).
Nguyen, CDL et al. Sensitive and simple targeted proteomics approach to quantify transcription factor and membrane proteins of the unfolded protein response pathway in glioblastoma cells. Science. representing 9(1), 8836 (2019).
Remes, PM, Yip, P. & MacCoss, MJ Highly multiplexed targeted proteomics enabled by real-time chromatographic alignment. Anal. Chem. 92(17), 11809–11817 (2020).
Pfammatter, S. et al. A novel differential ion mobility device increases the depth of proteome coverage and sensitivity of multiplex proteomics measurements. Mol. Cell. Proteomics 17(10), 2051-2067 (2018).
Bekker-Jensen, DB, del Val, AM, Steigerwald, S., Rüther, P., Fort, K., Arrey, TN, Harder, A., Makarov, A., Olsen, JV A compact quadrupole mass spectrometer- Orbitrap with the FAIMS interface improves proteome coverage in short LC gradients. Preprint at http://biorxiv.org/content/early/2019/11/30/860643.abstract.
Hebert, AS et al. One-shot complete proteomics with FAIMS on an Orbitrap Hybrid Mass Spectrometer. Anal. Chem. 90(15), 9529–9537 (2018).
Pfammatter, S., Bonneil, E., McManus, FP, and Thibault, P. Precise quantitative proteomic analyzes using metabolic labeling and high-field asymmetric waveform ion mobility spectrometry (FAIMS). J. Proteome. Res. 18(5), 2129-2138 (2019).
Schweppe, DK et al. Characterization and optimization of multiplexed quantitative analyzes using high-field asymmetric ion mobility mass spectrometry. Anal. Chem. 91(6), 4010-4016 (2019).
Hembrough, T. et al. Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue. J.Mol. Diag. 15(4), 454–465 (2013).
Guerin, M. et al. Development of quantitative proteomics based on parallel reaction monitoring (PRM) applied to HER2-positive breast cancer. Oncotarget 9(73), 33762–33777 (2018).
Steiner, C. et al. Quantification of HER2 by targeted mass spectrometry in formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue. Mol. Cellular proteomics 14(10), 2786–2799 (2015).
Kennedy, JJ et al. Demonstrate the feasibility of large scale development of standardized assays to quantify human proteins. National Methods 11149 (2013).